Introduction {#sec1}
============

Multidrug resistant (MDR) pathogenic bacteria cause nowadays more than 700,000 deaths per year in the world, affecting developing and developed countries, rural and urban areas, hospitals, farms and communities[^1^](#fn001){ref-type="fn"}. Since the emergence of MDR pathogenic bacteria is an urgent global risk that remains unsolved, it is imperative to strengthen antimicrobial use regulations and foster innovative research on new ways to combat bacteria. WHO has developed a global priority list of MDR pathogenic bacteria, in which *Staphylococcus aureus* is considered as Priority 2 (High), with the aim of helping to prioritize research and development of new antibiotic treatments[^2^](#fn002){ref-type="fn"}.

*S. aureus* is along with *Staphylococcus epidermidis* an important cause of bovine mastitis, the most widespread disease in dairy cattle ([@ref38]). These infections are very difficult to cure due to the ability of staphylococci (and *S. aureus*, in particular) to adhere and proliferate on animal tissues forming a biofilm that, together with somatic cells, clog milk canals within the mammary gland. This leads to an insufficient penetration of the antibiotic in the mammary gland when infused into the udder. Moreover, the increasing rate of MDR strains; and the ability of *S. aureus* to persist within mammary gland epithelial cells in a low metabolic state, thereby evading antibiotic treatment, is the main cause of recurrent and chronic infections associated to mastitis infections ([@ref21]). Apart from the derived economic losses, mastitis is also the main cause of antibiotic use in the dairy industry ([@ref30]). However, the increasing generation of MDR pathogenic bacteria is promoting a more restrictive use of antimicrobials in animal husbandry that is totally banned in some countries as prophylactic in animal feed ([@ref14]).

Over the last years, the study of bacteriophage-encoded lytic proteins, including endolysins and virion-associated peptidoglycan hydrolases (VAPGHs), for the treatment of infectious diseases has attracted great interest ([@ref18]; [@ref46]). These enzymes kill bacteria through peptidoglycan degradation followed by osmotic lysis. A pipeline portfolio recently published in The Lancet Infectious Diseases, highlighted endolysin-based antimicrobials as the compounds with the greatest potential to be used as novel therapeutics ([@ref8]). Indeed, there is evidence that many phage lytic proteins (enzybiotics) are effective in animal models of infection ([@ref53]) and also clinical phase I trials have been completed without the observation of adverse effects ([@ref31]). Phage lytic proteins have also been proposed as potential disinfectants for the food industry ([@ref26]) due to their rapid bactericidal action and biodegradability.

Most endolysins from phages infecting Gram-positive bacteria have a modular structure ([@ref40]), which facilitates protein engineering *via* domain shuffling to obtain new chimeric proteins with improved lytic activity ([@ref5]). Regarding *S. aureus*, several published reports have shown the effectiveness of phage lytic proteins as therapeutics ([@ref55]), biopreservatives ([@ref9]) and disinfectants ([@ref27]).

In our previous work, we identified and characterized four *S. aureus* infecting phages, the siphophages phiIPLA88 and phiIPLA35 and the myophages phiIPLA-RODI and phiIPLA-C1C ([@ref19]; [@ref28]). Two phage lytic proteins were identified in phage phiIPLA88, the endolysin LysH5 and the VAPGH protein HydH5 ([@ref39]; [@ref49]). Endolysin LysH5 has showed lytic activity against *S. aureus* in pasteurized milk ([@ref39]; [@ref20]) and also against staphylococcal biofilms ([@ref27]). Moreover, chimeric proteins derived from HydH5 and the bacteriocin lysostaphin were also obtained by combination of domains. The chimeric protein CHAPSH3b (CHAP domain from HydH5 and the SH3b CBD from lysostaphin) showed the highest specific activity ([@ref48]). Subinhibitory doses of this chimeric protein can prevent *S. aureus* biofilm formation through the downregulation of autolysin-encoding genes ([@ref17]). Moreover, two novel endolysins from phages phiIPLA35 and phiIPLA-RODI (*orf60* and *orf57*, respectively) were identified ([@ref19]; [@ref28]).

In this work, we have compared the main properties, in terms of enzymatic activity, of three phage lytic proteins; the two novel endolysins LysRODI and LysA72, and the chimeric protein CHAPSH3b. In a first step, a selection of the highest active proteins was performed based on *in vitro* experiments. Then, they were further validated *in vivo* using a systemic infection model in zebrafish. Finally, the ability of the most active protein (i.e. LysRODI) to prevent staphylococcal-induced mastitis was analyzed in lactating mice.

Materials and Methods {#sec2}
=====================

Bacterial Strains and Culture Conditions {#sec3}
----------------------------------------

The staphylococcal strains used in this study ([Table 1](#tab1){ref-type="table"}) were grown in tryptic soy broth (TSB; Difco, Franklin Lakes, NJ) at 37°C with shaking at 250 rpm or on TSB plates containing 2% (wt/vol) bacteriological agar (TSA). *Escherichia coli* BL21 (DE3) was used for protein expression grown at 37°C with shaking in LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl) or on plates of LB supplemented with 2% (w/v) agar. For proper selection of the clones, 100 μg/ml of ampicillin (Sigma Aldrich, Madrid, Spain) were added.

###### 

*Staphylococcus* spp. strains used in this work.

  Specie               Strain                                                                                                                  Origin                                  Reference   MIC (μM)[^a^](#tfn1){ref-type="table-fn"}                
  -------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------- ----------- ------------------------------------------- ------------ --------------
                                                                                                                                                                                                   **LysRODI**                                 **LysA72**   **CHAPSH3b**
  *S. aureus*          Sa9                                                                                                                     Milk from cows with clinical mastitis   [@ref19]    0.57                                        1.47         0.33
  Sa10                 0.57                                                                                                                    1.47                                    0.33                                                                 
  15,981               Human clinical isolate. Strong biofilm former                                                                           [@ref57]                                1.15        1.47                                        0.66         
  ATCC^®^ 25923™       Human clinical isolate with the designation Seattle 1945 that is used as a standard laboratory testing control strain   ATCC strain                             0.57        1.47                                        0.66         
  7,829                Pig skin. Methicillin-resistant *S. aureus* (MRSA)                                                                      Unpublished                             1.15        5.88                                        0.66         
  Staph. 15            Human clinical isolate. Methicillin-resistant *S. aureus* (MRSA)                                                        Unpublished                             1.15        5.88                                        1.33         
  *S. epidermidis*     F12                                                                                                                     Milk from woman with mastitis           [@ref11]    1.15                                        \>23.52      0.33
  B                    0.57                                                                                                                    \>23.52                                 0.33                                                                 
  DG2n                 1.15                                                                                                                    \>23.52                                 1.33                                                                 
  LV5RB3               Milk from healthy woman                                                                                                 [@ref11]                                2.29        \>23.52                                     0.33         
  *S. sciuri*          101                                                                                                                     Milk from healthy woman                 [@ref37]    4.59                                        \>23.52      0.33
  *S. hominis*         ZL31--13                                                                                                                1.15                                    \>23.52     0.33                                                     
  *S. pasteuri*        ZL16--6                                                                                                                 2.29                                    \>23.52     0.66                                                     
  *S. xylosus*         ZL61--2                                                                                                                 1.15                                    \>23.52     0.66                                                     
  *S. saprophyticus*   ZL112--15                                                                                                               0.15                                    \>23.52     0.66                                                     
  *S. arlattae*        ZL114--5                                                                                                                1.14                                    \>23.52     0.66                                                     
  *S. haemolyticus*    ZL89--3                                                                                                                 0.57                                    1.47        0.33                                                     
  *S. gallinarum*      ZL90--5                                                                                                                 1.14                                    \>23.52     0.33                                                     
  *S. kloosii*         ZL74--2                                                                                                                 1.14                                    \>23.52     0.66                                                     

*Minimum inhibitory concentration (MIC) expressed as μM*.

*Data represent the mode of three independent biological repeats*.

Structural and Functional Bioinformatics Analysis of the Endolysins {#sec4}
-------------------------------------------------------------------

The protein sequences of LysRODI (Genbank accession number YP_009195893.1) and LysA72 (Genbank accession number YP_002332423.1) were analyzed using BLASTP ([@ref1]) and HMMER v3.2.1[^3^](#fn003){ref-type="fn"} in order to identify the enzymatic activity domains. The protein sequences were compared with those from staphylococcal phage endolysins available in public databases (Pubmed, accessed January 2019) by CLUSTAL W alignment using Geneious 7.1.3[^4^](#fn004){ref-type="fn"}. The 3D structure of the proteins was predicted using the web-based server Phyre2 ([@ref33]).

Plasmid Construction and DNA Manipulation {#sec5}
-----------------------------------------

The genes encoding LysRODI (Gene ID: 26623165) and LysA72 (GeneID: 7057022) were optimized based on *E. coli* codon usage by the OptimumGene™ codon optimization technology[^5^](#fn005){ref-type="fn"}. Additionally, *Nd*eI and *Xho*I restriction sites were added at the 5′ and 3′ end, respectively. The optimized sequences were synthetized and cloned into the pET21a vector by GenScript (Township, NJ, USA). This vector introduces a C-terminal His~6~-tag and carries an ampicillin resistance gene. The pET21a vector containing the gene was then transformed into *E. coli* BL21 (DE3). The clones overexpressing CHAPSH3b were obtained in a previous study ([@ref48]).

Protein Overexpression, Purification and Endotoxin Removal {#sec6}
----------------------------------------------------------

Protein expression was performed by induction with 1 mM IPTG (isopropyl-ß-D-thiogalactopyranoside) and incubation at 16°C, 16 h, as previously described ([@ref22]). For control purposes for *in vivo* experiments, *E. coli* BL21 cells transformed with the empty pET21a vector were used and purified as the rest of the proteins (MOCK control). After protein expression, cells were centrifuged (10,000 rpm, 4°C, 15 min) and suspended in 10 ml of lysis buffer (20 mM NaH~2~PO~4~, 500 mM NaCl, 10 mM imidazole, pH 7.4). Pellets were freeze/thawed three times at −80°C. Sonication was carried out afterwards (15 × 5 s pulses with 15 s recovery on ice; 40% of amplitude). Then, the suspension was centrifuged at 10,000 rpm, 4°C, 30 min. Proteins were purified by immobilized metal ion affinity chromatography using nickel-NTA Superflow resin columns (Qiagen, Valencia, CA, USA) following supplier's recommendations. Briefly, 1 ml of resin was added to 10 ml of protein lysate. This mixture was incubated at 4°C for 16 h with slow shaking and then loaded onto 5 ml columns (BioRad, Hercules, CA, USA). For purification and endotoxin removal, a protocol described previously was performed ([@ref45]). When using the protein for *in vivo* experiments (endotoxin-free), columns were washed with 50 ml of lysis buffer supplemented with 0.1% Triton X-114. Afterwards, columns were washed with 20 ml of lysis buffer and 50 ml of wash buffer (20 mM NaH~2~PO~4~, 500 mM NaCl, 20 mM imidazole, pH 7.4). For all other experiments, Triton X-114 was omitted and columns were washed with 30 ml of lysis buffer and 50 ml of wash buffer instead. Finally, the purified proteins were recovered with 1.5 ml of elution buffer (20 mM NaH~2~PO~4~, 500 mM NaCl, 250 mM imidazole, pH 7.4) and subsequently stored at −80°C in the presence of 30% glycerol to prevent precipitation.

Protein purity was evaluated in 12% (vol/wt) SDS-PAGE run at 150 V using Criterion precast gels (BioRad), and further revealed *via* conventional Coomassie staining. Protein concentration was quantified by the Quick Start Bradford Protein assay (BioRad).

Prior to the experiments, the buffer was exchanged to 50 mM sodium phosphate (NaPi) buffer (pH = 7.4) using "Zeba™ Spin Desalting Columns, 7K MWCO, 5 ml" (Thermo Fisher Scientific, Madrid, Spain) following the supplier's recommendations. Finally, proteins were filtered (0.45 μm PES membrane filters; VWR, Spain).

Quantification of Specific Lytic Activity {#sec7}
-----------------------------------------

Turbidity reduction assay was performed as previously described ([@ref39]) using *S. aureus* Sa9 cells suspended in NaPi buffer (50 mM; pH = 7.4) and treated with two-fold dilutions of the purified proteins (0.02--50 μM). Results were expressed as specific lytic activity (ΔOD~600~ × min^−1^ × μM^−1^) ([@ref13]). To evaluate the effect of several cations on enzymatic activity, different salts (KCl, MgCl~2~, NaCl, MnCl~2~, ZnCl~2~, CaCl~2~) were added at a final concentration of 10 mM. The effect of temperature in protein activity was evaluated by incubating an aliquot of the protein for 30 min at different temperatures (40--90°C), followed by a turbidity reduction assay. In addition, the effect of pH on activity was tested by diluting (1:100) the proteins into Britton-Robinson buffer (150 mM KCl, 10 mM KH~2~PO~4~, 10 mM sodium citrate, 10 mM H~3~BO~3~) adjusted to pH 3 to 11. In this case, the turbidity reduction assay was carried out with the *S. aureus* Sa9 cells also suspended in the Britton-Robinson buffer. All experiments were performed in triplicate.

Minimum Inhibitory Concentration (MIC) of Phage Lytic Proteins {#sec8}
--------------------------------------------------------------

The MIC of the proteins was determined in triplicate by the conventional broth microdilution technique in TSB ([@ref6]). The MIC was defined as the lowest protein concentration that inhibited visible bacterial growth after 24 h of incubation at 37°C and expressed as the mode of three replicates.

Time-Killing Assays {#sec9}
-------------------

The antibacterial activity was performed as previously described ([@ref47]) using as substrate *S. aureus* Sa9 diluted in TSB (\~10^7^ CFU/ml) and 0.1 μM of each protein. As a control for bacterial growth, 50 mM sodium phosphate (NaPi) buffer (pH = 7.4) were added instead of the proteins. The cultures were incubated at 37°C with shaking (250 r.p.m) and 50 μl of samples were taken at different time points (2--60 min). Reaction was immediately stopped by adding 0.15 μg of proteinase K. Bacterial dilutions were then plated onto TSA and incubated at 37°C for 16 h. The antibacterial activity of three independent replicates was quantified as the relative inactivation in log units \[log~10~(*N*~0~/*N*~i~) with *N*~0~ as the initial number of untreated cells and N~i~ as the number of residual cells counted after treatment\] ([@ref47]).

Development of Bacterial Resistance to Lytic Proteins {#sec10}
-----------------------------------------------------

Resistance development was tested using repeated exposures to protein concentrations according to the minimal inhibitory concentration (MIC) assays ([@ref4]). Two-fold serial dilutions of the proteins (0.02--50 μM) were used against *S. aureus* Sa9 (10^6^ CFU) and *S. epidermidis* F12 (10^6^ CFU) grown in a 96 polystyrene microtiter plate at 37°C for 16 h. The next day, 100 μl of the first well with growth (0.5 × MIC) were inoculated into 5 ml of TSB and grown to an OD~600~ = 0.5. These cultures were used for the next round of MIC exposure. The experiment was repeated for 10 rounds, followed by 5 additional rounds in TSB without the protein in order to allow phenotype reversion. Then MIC assay was further performed to measure the sensitivity to the proteins. Experiments were performed using three independent biological replicates. As a positive control of the experiment, the bacteriocin lysostaphin (Sigma, Missouri, USA), produced by *Staphylococcus simulans*, was also tested.

Biofilm Assays {#sec11}
--------------

Staphylococcal biofilm formation and removal was performed as previously described using the RTCA technology ([@ref25]; [@ref23]). Briefly, 100 μl of *S. aureus* 15,981 were diluted in TSBg (TSB supplemented with 0.25% w/v D-(+)-glucose) and poured into 16-well E-plates (∼10^6^ CFU/well). E-plates were connected to the xCelligence RTCA-DP (ACEA Biosciences Inc., San Diego, CA, USA) holder which measure the impedance signal and represent cell index (CI) values. Biofilm were formed for 8 h at 37°C and then 100 μl of LysRODI and LysA72 were added to achieve a concentration gradient (0.14--9.15 μM and 0.21--13.42 μM, respectively) and incubated for an extra 16 h. Impedance values were further processed using the RTCA software 1.2.1 (ACEA Biosciences Inc.) as described previously ([@ref23]) in order to calculate: (i) the percentage of biofilm removal compared to control values after 16 h of treatment; (ii) the minimum biofilm eradicating concentration that removes 50% of the biofilm (MBEC~50~), (iii) the lowest antibiofilm effect (LOABE; lowest concentration needed to observe an antibiofilm effect) and (iv) the specific antibiofilm activity expressed as Δbaseline normalized CI × min^−1^ × mM^−1^. All the experiments were performed in triplicate.

Safety and Efficacy of the Proteins in Zebrafish {#sec12}
------------------------------------------------

Safety and efficacy of LysRODI and CHAPSH3b were evaluated in two zebrafish models (IKAN Biotech, Navarra, Spain; [www.ikanbiotech.com](http://www.ikanbiotech.com)). The experiments and protocols were performed according to the Organization for Economic Cooperation and Development (OECD) following the Standard Guide for Conducting Acute Toxicity Tests (ASTM) and ISO 20776-1:2007 regulations, achieving the Good Laboratory Practices.

Safety was evaluated by the acute toxicity induced in zebrafish embryos by 1 × MIC of the correspondent protein. To do this, eggs were collected after fecundation and kept in a Petri dish containing E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl~2~, 0.33 mM MgSO~4~, 0.0001% methylene blue) at 34°C until the next day. Zebrafish embryos (*n* = 8) were individually placed in 96-well microplates and 100 μl of the protein was added (0.73 μM for LysRODI and 0.55 μM for CHAPSH3b). As negative and positive controls, 100 μl of E3 medium and 100 μl of E3 supplemented with 1 mg/ml paracetamol (Alfa Aesar, VWR) ([@ref500]) were used, respectively. The plates were incubated at 34°C and observations were recorded after 72 h. To evaluate the toxicity of the proteins, all embryos were visually inspected (apical parameters, sub-lethal or teratogenic symptoms and mortality). Results are expressed as percentage of surviving embryos. To assess the reproducibility of the model, each experiment (*n* = 8) was performed in triplicate.

To test the lytic efficacy of LysRODI and CHAPSH3b, a systemic model of *S. aureus* infection in adult zebrafish was used. First, zebrafish (*n* = 18) were kept at 34°C for 24 h. Fish were then anesthetized with tricaine MS-222 (Sigma-Aldrich) for 10 min and, intraperitoneally inoculated with 10 μl of a suspension containing \~10^5^ CFU/fish of *S. aureus* ATCC^®^ 25923™, using a Hamilton syringe with 31G gauge needles (BD Microlance). After 1-h post-infection, fish were treated with different concentrations (1 × MIC, 0.5 × MIC or 3 × MIC) of LysRODI or CHAPSH3b, and kept at 34°C for 72 h. The number of surviving zebrafish was recorded for 72 h post-treatment. As control, adult zebrafish (*n* = 18) were infected with the bacteria and inoculated with 0.85% of sodium chloride solution (Sigma Aldrich). The percentage of cumulative survival zebrafish was represented by the Kaplan--Meier analysis.

Efficacy in a Mouse Model of Mastitis {#sec13}
-------------------------------------

Male and female CD1 mice of 20--22 g bodyweight were purchased at Charles River International (France) and accommodated in the animal facilities of the "Instituto de Agrobiotecnología" (registration code ES/31-2016-000002-CR-SU-US) with water and food *ad libitum*. Mice handling and procedures were performed in compliance with the current European and International regulations, following the welfare guidelines and recommendations of the Federations of European Laboratories of Animal Science Associations (FELASA) ([@ref44]) and Animal Research Reporting of *in vivo* Experiments (ARRIVE) ([@ref34]) and the study was approved by the Comité de Ética, Experimentación Animal y Bioseguridad (CEEAB) of the Public University of Navarra (PI/018-19).

Pregnancies were synchronized by circadian cycle adjustment and introduction of males in the same cage for 3 days. Ten days after delivery, the offspring were removed and the lactating females (*n* = 7) were treated intramammary. For that, mice were intraperitoneally anesthetized with a mixture of ketamine 100 mg/kg (Imalgene^®^, Merial Laboratorios, S.A) and xylacine 10 mg/kg (Rompun^®^, Bayer Health Care), and, then, treated in the R4 teat by intramammary administration of 0.1 ml containing 24 μg/mouse of LysRODI (*n* = 7) or PBS (*n* = 4) by using a 33 gauge blunt-end needle in a Hamilton syringe (Hamilton). All mice were challenged at 90 min post-treatment, by intramammary inoculation of 5 × 10^4^ CFU/mouse of *S. aureus* Sa10 or *S. epidermidis* B, and, 18 h later, the R4-R5 mammary glands were aseptically removed, individually weighed, serially diluted in PBS (1:9) and plated in agar, in order to determine the number of CFU/gland. An additional control group (*n* = 3) was intramammary inoculated with MOCK buffer and challenged with one of the pathogens (i.e. *S. epidermidis* B) as before. Clinical signs of hyperemia or edema with changes in color, texture or size of the mammary gland were determined by visually inspection after the treatment.

Statistical Analysis {#sec14}
--------------------

The SPSS Statistics for Windows V. 22.0 (IBM Corp.) was used for all calculations. The data obtained from the *in vitro* activity tests (specific lytic activity, time-kill assays, biofilm assays and determination of bacterial resistance) were expressed as the mean ± standard deviation of three biological replicates. One-way ANOVA followed by the Student--Newman--Keuls (SNK) or Protected Least Significant Differences (PLSD) post-hoc tests, were used to determine differences in protein activity and also in the mouse model of mastitis. On the other hand, the student t-test was used to compare the differences between the treated and untreated bacterial cultures at a level of significance *p* \< 0.05. Statistical comparison of surviving embryos fish was performed by Chi-square test. The percentage of cumulative survival zebrafish was calculated and plotted by Kaplan--Meier cumulative survival analysis and statistically compared by the Log-Rank test, using the StatView^®^ SAS package (SAS Institute Inc., Version 5).

Results {#sec15}
=======

New Endolysins LysRODI and LysA72 Were Identified From Phage Genomes {#sec16}
--------------------------------------------------------------------

Two new endolysins encoded by bacteriophages infecting *S. aureus* (phiIPLA-RODI and phiIPLA35) were identified (LysRODI and LysA72, respectively) ([@ref19]), ([@ref28]). Bioinformatics analysis of these proteins revealed that both possess a modular structure composed by two catalytic domains (CHAP and amidase) and one SH3b cell wall binding domain. LysRODI possesses an amidase belonging to the "type 2" family, while LysA72 carries an amidase "type 3" ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). The predicted 3D structure of the proteins using Phyre2 revealed a modular organization of the domains clearly separated by a linker region ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). LysRODI exhibited a high similarity (\>98%) with other endolysins available in public databases, more specifically with those encoded by staphylococcal *Myoviridae* phages ([Supplementary Figure 2A](#SM1){ref-type="supplementary-material"}). On the other hand, LysA72 has a high similarity with endolysins encoded by other staphylococcal siphophages ([Supplementary Figure 2B](#SM1){ref-type="supplementary-material"}).

Following computer analysis, the genes coding for LysRODI (54.8 kDa) and LysA72 (53.8 kDa) were cloned into the expression vector pET21a and overexpressed in *E. coli* BL21 (DE3). Nevertheless, after the purification process, proteins LysRODI and LysA72 were not completely soluble, and the concentration of purified protein was 0.6 and 0.3 mg/ml, respectively. To improve the purification efficiency, the endolysin-encoding genes were optimized for expression in *E. coli*. The new constructs resulted in completely soluble proteins with an increased purification yield (2.5 and 1.1 mg/ml, respectively). The chimeric protein CHAPSH3b (30.4 kDa) was purified as described previously with a yield of 0.9 mg/ml ([@ref48]).

LysRODI Shows a High Lytic Activity Against a Broad Range of Staphylococcal Species {#sec17}
-----------------------------------------------------------------------------------

The minimum inhibitory concentration (MIC) of the three proteins was calculated against a collection of staphylococcal species including strains from different origins ([Table 1](#tab1){ref-type="table"}). It is worth noting that LysA72 was active only against *S. aureus* and *S. haemolyticus* strains, while LysRODI and CHAPSH3b were able to lyse all the tested staphylococcal species and displayed lower MIC values ([Table 1](#tab1){ref-type="table"}).

Regarding the specific lytic activity (ΔOD~600~ × min^−1^ × μM^−1^), LysRODI and CHAPSH3b showed similar results and were again the most active (*p* \< 0.05) ([Table 2](#tab2){ref-type="table"}).

###### 

Specific lytic activity of the proteins against *S. aureus* Sa9 and *S. epidermidis* F12.

             Specific lytic activity   
  ---------- ------------------------- -------------
  LysRODI    0.24 ± 0.02               0.12 ± 0.03
  LysA72     0.09 ± 0.00               N.A.
  CHAPSH3b   0.20 ± 0.02               0.11 ± 0.02

*Data are expressed as the mean ± standard deviation of three replicates and expressed as ΔDO~600~ × μM^−1^× min^−1^*.

*N.A.: Not active*.

Protein Stability and Activity Is Influenced by Different Physicochemical Conditions {#sec18}
------------------------------------------------------------------------------------

The stability of the proteins and the influence of two environmental parameters (temperature and pH) on the lytic activity against *S. aureus* Sa9 was determined. The exposure to temperatures over 40°C completely inactivated LysA72, while LysRODI showed a decreased activity at this temperature and was inactivated at higher temperatures. CHAPSH3b completely retained its activity at 40°C, and even showed some residual activity at higher temperatures ([Figure 1A](#fig1){ref-type="fig"}). Regarding pH, the most stable protein was CHAPSH3b, which showed a high activity in a broad range of pH (3--11). In turn, LysRODI and LysA72 showed the highest activity at pH 7, albeit LysRODI was active within pH 5 and 9 ([Figure 1B](#fig1){ref-type="fig"}).

![Influence of environmental parameters **(A)** temperature and **(B)** pH on protein activity. Specific lytic activity of the proteins is calculated against *S. aureus* Sa9. Bars represent the activity (ΔDO~600~ × min^−1^ × μM^−1^) of each protein (LysRODI, black; LysA72, gray and CHAPSH3b white). Data are the mean ± standard deviation of three biological replicates. Asterisks indicate statistical differences (*p* \< 0.05; Student's *t*-test) between the specific lytic activity when the protein is submitted to the temperature or pH treatment with the activity observed when the protein is tested at 37°C in NaPi buffer, pH = 7.4. The data were expressed as the mean ± standard deviation of three biological replicates.](fmicb-11-00007-g001){#fig1}

Finally, the influence of different ions (KCl, MgCl~2~, NaCl, MnCl~2~, ZnCl~2~, CaCl~2~) on lytic activity was also evaluated. LysRODI was completely inactivated in the presence of MnCl~2~, ZnCl~2~ and MgCl~2~. Interestingly, ZnCl~2~ also resulted inhibitory for LysA72 and CHAPSH3b. Of note, the activity of proteins LysRODI, LysA72 and CHAPSH3b increased \~2-fold by adding NaCl, CaCl~2~ and KCl (data not shown).

Chimeric Protein LysRODI and CHAPSH3b Lyse Staphylococcal Cells Faster Than LysA72 {#sec19}
----------------------------------------------------------------------------------

To determine the killing rate of phage lytic proteins, time-kill curve experiments were performed using *S. aureus* Sa9 cultures (10^7^ CFU/ml) treated with equimolar amounts of each protein (0.1 μM). In these assays, LysRODI and CHAPSH3b showed a higher antibacterial activity than LysA72, as both of them reduced the bacterial counts under the detection limit after 30 min ([Figure 2](#fig2){ref-type="fig"}). Of note, CHAPSH3b was faster than the other two proteins since a 4.5 log reduction in viable counts was observed after only 2 min of incubation. At this same time, a 3.5 log reduction was observed for LysRODI. Unfortunately, LysA72 did not achieve a complete elimination of the bacteria ([Figure 2](#fig2){ref-type="fig"}).

![Time-kill curve of *S. aureus* Sa9 treated with equimolar amounts (0.1 μM) of proteins (LysRODI, black; LysA72, gray and CHAPSH3b white). Results (means ± standard deviation of three replicates) are reported as bacterial reduction quantified as the relative inactivation in log units (log~10~\[N~0~/N~i~\]; N~0~ as the initial number of untreated cells and N~i~ as the number of residual cells counted after treatment). Bars having an asterisk are statistically different (*p* \< 0.05) from the untreated control according to the Student's t-test. The detection limit is 10 CFU/ml.](fmicb-11-00007-g002){#fig2}

Neither the Endolysins nor CHAPSH3b Lead to Staphylococcal Resistance Development {#sec20}
---------------------------------------------------------------------------------

To assess the ability of *S. aureus* and *S. epidermidis* to develop resistance against the phage lytic proteins, we attempted to select resistant mutants in liquid medium by serial subculture of staphylococcal strains in the presence of sub-inhibitory concentrations of the proteins. Lysostaphin was used as a positive control. After 10 rounds of exposure, MIC values were determined and compared with the ones obtained previously for two strains susceptible to the three lytic proteins ([Table 3](#tab3){ref-type="table"}). As expected, the MIC values of lysostaphin increased by more than 32-fold, whereas the studied proteins did not select resistant bacteria.

###### 

MIC values of *S. aureus* Sa9 and *S. epidermidis* F12 before (Control) and after (Treated) exposure to sub-lethal concentrations of different recombinant phage proteins.

  Strain                                     Assay         MIC (μM)[^a^](#tfn3){ref-type="table-fn"}                          
  ------------------------------------------ ------------- ------------------------------------------- ------------- -------- ------
  *S. aureus* Sa9                            Control       0.57                                        1.47          0.33     0.43
  Treated[^b^](#tfn4){ref-type="table-fn"}   0.49 ± 0.11   1.39 ± 0.24                                 0.39 ± 0.16   \>27.6   
  *S. epidermidis* LO5081                    Control       1.14                                        2.94 ± 0.09   0.33     1.73
  Treated[^b^](#tfn4){ref-type="table-fn"}   1.17 ± 0.06   2.48 ± 0.11                                 0.32 ± 0.01   \>27.6   

*Minimum inhibitory concentration (MIC) expressed as μM*.

*MIC values after 10 rounds of exposure to protein followed by five additional rounds without protein*.

*Data represent the mean ± standard deviation of three independent biological repeats*.

LysRODI Shows the Highest and Fastest Antibiofilm Activity *in vitro* {#sec21}
---------------------------------------------------------------------

Four different antibiofilm parameters were calculated for the endolysins LysRODI and LysA72 and compared to those previously obtained for CHAPSH3b ([@ref23]) ([Table 4](#tab4){ref-type="table"}). The MBEC~50~ and the LOABE were calculated after treating 8 h preformed biofilms of *S. aureus* 15,981 (a strong biofilm former) with increasing concentrations of the proteins (0.14--9.15 μM for LysRODI and 0.21--13.42 μM for LysA72) ([Table 4](#tab4){ref-type="table"}). LysA72 exhibited the highest MBEC~50~ (minimum biofilm eradication concentration) and LOABE (lowest concentration of protein needed to observe an antibiofilm effect) values indicating that a higher concentration is necessary to attain the same antibiofilm effect. In turn, LysRODI possessed the lowest MBEC~50~ value of all three proteins, since only 2.21 μM could remove 50% of the biofilm.

###### 

Antibiofilm activity of LysRODI, LysA72 and CHAPSH3b.

  Protein                                     MBEC~50~ (μM)[^a^](#tfn5){ref-type="table-fn"}   LOABE (μM)[^b^](#tfn6){ref-type="table-fn"}   Specific antibiofilm activity[^c^](#tfn7){ref-type="table-fn"}   Biofilm reduction (%)[^d^](#tfn8){ref-type="table-fn"}
  ------------------------------------------- ------------------------------------------------ --------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------
  LysRODI                                     2.21 ± 0.22                                      1.14                                          4.53 ± 0.63                                                      94.23 ± 4.59
  LysA72                                      13.26 ± 3.87                                     13.42                                         0.12 ± 0.02                                                      17.13 ± 2.63
  CHAPSH3b[^e^](#tfn9){ref-type="table-fn"}   4.4 ± 1.2                                        1.2                                           0.38 ± 0.03                                                      25.62 ± 6.23

*MBEC~50~: minimum biofilm eradicating concentration that removes 50% of the biofilm*.

*LOABE: lowest antibiofilm effect. MBEC~50~ and LOABE were calculated for S. aureus 15,981 8 h mature biofilms treated with increasing concentrations of protein*.

*Specific antibiofilm activity expresses as the mean ± standard deviation of (Δbaseline normalized CI × mM^−1^ × min^−1^) using 7 μM of protein*.

*% of biofilm reduction expresses as the mean ± standard deviation (n = 3) of normalized CI using 7 μM of protein at 16 h post-treatment and 37°C*.

*These data have been previously published (22). All data represent mean ± standard deviation of three biological replicates*.

In order to compare the specific antibiofilm activity of the proteins, an equimolar amount of protein (7 μM) was used to treat the biofilms ([Table 4](#tab4){ref-type="table"}). Interestingly, LysRODI showed the highest specific antibiofilm activity (\~4.5), being 11 and 38 times more active than CHAPSH3b and LysA72, respectively. This result indicates a faster antibiofilm activity of LysRODI, since maximum biofilm removal was achieved 1 h after treatment, while for CHAPSH3b and LysA72 the maximum reduction was achieved after 2.5 and 5 h, respectively (data not shown). Moreover, the percentage of biofilm reduction after 16 h of treatment with LysRODI was 94% but only 25 and 17% when treated with CHAPSH3b and LysA72, respectively ([Table 4](#tab4){ref-type="table"}).

Both LysRODI and CHAPSH3b Are Safe and Show Anti-Staphylococcal Activity in Zebrafish {#sec22}
-------------------------------------------------------------------------------------

Based on the *in vitro* activity data, LysRODI and CHAPSH3b were assessed *in vivo* in a zebrafish model. Initially, acute toxicity was evaluated by exposure of zebrafish embryos to 1 × MIC of LysRODI (0.5 μM) and CHAPSH3b (0.7 μM). As expected, treatment with 1 mg/ml of paracetamol was toxic for the embryos ([Figure 3A](#fig3){ref-type="fig"}). In protein-treated groups embryos survived in presence of LysRODI and CHAPSH3b (\>92% survival), indicating a non-toxic effect ([Figure 3A](#fig3){ref-type="fig"}).

![Evaluation of safety and activity of LysRODI and CHAPSH3b using a zebrafish model. **(A)** Acute toxicity of the proteins was tested by exposure of zebrafish embryos (*n* = 8) to 1 × MIC of LysRODI or CHAPSH3b. Medium E3 was used as a negative control and 1 mg/ml paracetamol, as a positive control. Bars represent mean ± standard deviation (*n* = 24) of triplicate experiments. The asterisk indicates statistical differences (*p* \< 0.05) *vs* untreated control by Chi-square test. **(B)** Efficacy of LysRODI (I) and CHAPSH3b (II) in a zebrafish model infected with \~10^5^ CFU/fish of *S. aureus* when treating with 0.5 × MIC, 1 × MIC and 3 × MIC. Kaplan--Meier graphs represent the percentage of cumulative survival zebrafish (*n* = 18) observed at 24, 48 and 72 h. Asterisks indicate significant differences (*p* \< 0.05) *vs.* the untreated control according to the Kaplan--Meier cumulative survival plot and statistically compared by the Log-Rank test.](fmicb-11-00007-g003){#fig3}

Once established the lack of toxicity of the lytic proteins, their protective effect against a subsequent bacterial challenge was evaluated in a systemic model of infection. As expected, the untreated zebrafish control infected with *S. aureus* showed a 33.3% of cumulative survival after 72 h ([Figure 3B](#fig3){ref-type="fig"}). In contrast, treatment with three different doses (0.5 × MIC, 1 × MIC or 3 × MIC) of LysRODI (0.25, 0.5 and 1 μM) or CHAPSH3b (0.35, 0.7 and 1.4 μM) significantly improved survival of the infected animals (*p* = 0.0028 and *p* = 0.0002, respectively), with similar levels of efficacy obtained for both proteins testing 3 different concentrations (*p* \> 0.05; [Supplementary Table 1](#SM1){ref-type="supplementary-material"}). In fact, at 72 h after treatment, MIC and 0.5 × MIC of both proteins allowed a 66.7 and 83.3% survival, respectively, although these differences were not statistically significant (*p* \< 0.05). Of note, 3 × MIC of LysRODI led to a 77.7% survival, which is not statistically significant compared to the other two concentrations tested (*p* \< 0.05). Meanwhile, 3 × MIC of CHAPSH3b led to a 94.4% of survival which is statistically significant (*p* \> 0.05) when compared with 0.5 × MIC, indicating a dose-dependent effect. Besides, the treatment with 3 × MIC of CHAPSH3b or LysRODI gave similar results (*p* \< 0.05) Moreover, no viable bacteria could be detected in any of the surviving fish 72 h post infection (data not shown).

LysRODI Prevents Staphylococcal Infection in a Mouse Model of Mastitis {#sec23}
----------------------------------------------------------------------

LysRODI was selected to evaluate its *in vivo* ability to prevent *S. aureus* and *S. epidermidis* mastitis in a murine model, since it showed the most effective antibiofilm activity and its *in vivo* activity was dose-independent in a zebrafish infection model. Intramammary treatment with LysRODI in mice prevented the mastitis lesions ([Figure 4A](#fig4){ref-type="fig"}) and significantly reduced the bacterial virulent infection caused by *S. aureus* (*p* \< 0.001) or *S. epidermidis* (*p* \< 0.0001) ([Figure 4B](#fig4){ref-type="fig"}). Indeed, mice treated with the endolysin showed healthy mammary glands in terms of color, texture, size and absence of edema or hyperemia, in contrast to untreated controls ([Figure 4A](#fig4){ref-type="fig"}). Regarding the bacterial burden, LysRODI treated mice showed a reduction of 3--4 log units compared to the untreated mice controls ([Figure 4B](#fig4){ref-type="fig"}).

![Efficacy of LysRODI preventive treatment in a mastitis mouse model. CD1 lactating mice at breastfeeding day 10 were treated by intramammary administration of 24 μg of LysRODI and challenged 90 min later with 5 × 10^4^ CFU/mice of *S. epidermidis* or *S. aureus.* Mice inoculated with PBS or mock buffer were used as controls of staphylococcal infection. **(A)** Macroscopic aspect of R4-R5 mammary glands of mice treated with (I) treated 24 μg/mouse of LysRODI or (II) PBS and infected with *S. aureus* Sa10. Red arrows indicate symptoms of edema, hyperemia and changes in color of an infected mammary gland. **(B)** Preventive efficacy of LysRODI against *S. aureus* and *S. epidermidis* mammary glands infections in CD1 mice, determined by the mean ± standard deviation of individual log~10~ CFU/mammary gland. White symbols are Lys-RODI treated mice; black symbols are untreated mice, inoculated with either PBS or mock sterile buffers; circles and squares represent, respectively, *S. aureus* and *S. epidermidis* challenged mice. The number of CFU was determined in each R4-R5 mammary gland, at 18 h post-challenge. Statistical comparison of means was performed by ANOVA and post-hoc PLSD tests: ^\*\*^*p* \< 0.001 and ^\*\*\*^*p* \< 0.0001 vs. control (PBS or mock).](fmicb-11-00007-g004){#fig4}

Discussion {#sec24}
==========

Phage lytic proteins could potentially reduce the incidence of animal diseases while avoiding antibiotic use. In the case of *S. aureus* and *S. epidermidis* infections, prevention is perhaps a better strategy than treatment. For instance, once a staphylococcal infection is established, the bacterial cells can be found in an intracellular stage or forming antibiotic-resistant biofilms. Previous studies have shown that phage lytic proteins can be effective as a preventive strategy against staphylococcal infections by decolonization of skin and nares in murine models ([@ref16]; [@ref42]; [@ref43]).

The activity and stability of three proteins LysRODI, LysA72 and CHAPSH3b was firstly evaluated *in vitro* against staphylococcal strains isolated from human and farm animals. Activity was assessed by muralytic, MIC and time-kill assays ([@ref51]). The specific lytic activity of LysRODI was similar to that of the well-known endolysin LysK (\~0.04 ΔDO~600~ × min^−1^ × μg^−1^) ([@ref2]), with which it shares 98% of protein similarity. Interestingly, LysRODI and CHAPSH3b turned out to be active against all the species of staphylococci tested. This broad activity range is quite common among staphylococcal endolysins since their cell wall binding domain (CBD) have proven to recognize different staphylococcal species ([@ref3]; [@ref54]; [@ref24]). In addition to the CBD, the broad activity range can also be explained by the cleavage sites of the CHAP and amidase domains of staphylococcal endolysins, which are conserved in the peptidoglycan of both *S. aureus* and other staphylococcal species. Surprisingly, the activity of LysA72 seems to be restricted to *S. aureus* and *S. haemolyticus* strains. Unfortunately, it is difficult to determine if this narrow range is related to the protein structure because there is only one protein with a high similarity (98%) to LysA72 that has been purified to date; endolysins from phage phi12. The activity of this endolysin could not be determined due to cell aggregation during the turbidity assay, which led to an increase in optical density ([@ref50]). This phenomenon of cell aggregation was explained by the authors because of an aminoacidic exchange in position 260 (Amidase-3 domain), which is only present in the endolysin from phage phi12 but not in LysA72 or other related endolysins ([@ref3]).

Protein stability under a wide range of environmental conditions is very important for the development of endolysin-based antimicrobial products, especially those aimed for topical application. Both CHAPSH3b and LysRODI retained full activity for at least 30 min in skin-simulated conditions (pH between 4 and 7, temperature from 26 to 38°C) ([@ref35]). The activity of LysRODI under physicochemical disadvantages are in accordance with those previously obtained for LysK, both active within the same pH range (5--9), temperature (stable until 40°C) and are positively influenced by the addition of NaCl ([@ref2]).

Time-killing assays provide a good indication of the speed at which a given antimicrobial can kill bacterial cells, which in turn is indicative of its effectiveness to prevent infection progress. In this study, a similar time-killing speed was observed for LysRODI and CHAPSH3b, whereas LysA72 was slower and never caught up with the other two proteins in terms of total bacterial elimination. Generally, the quicker activity of endolysins is consistent with previous reports due to the high affinity of CBDs to the bacterial peptidoglycan ([@ref36]). Of note, the ability of LysRODI and CHAPSH3b to remove 7 log units of bacteria is even higher than that of CF-301, a lysin encoded within a prophage of the *Streptococcus suis* genome, whose domain arrangement is very similar to that of CHAPSH3b (CHAP domain and SH3b domain). In fact, addition of CF-301at its minimum inhibitory concentration only led to a reduction in bacterial cells of about 3 log units within 30 min ([@ref55]).

Attachment to host tissues and biofilm formation are processes of key importance for persistence and progress of bacterial infections ([@ref41]). In terms of preventive treatment, any successful strategy should hinder this process and display antibiofilm activity. Removal of preformed biofilms, however, is expected to be hindered by their maturation state and their complex three-dimensional structure, which limits access of antimicrobials to their target bacteria. Nonetheless, there are promising results with phage lytic proteins. In this study, LysRODI displayed the best antibiofilm activity on the basis of different antibiofilm parameters. Generally speaking, it has been demonstrated that complete removal of a mature biofilm (more than 24 h old biofilms) needs a second endolysin treatment ([@ref27]) or a combined treatment with antibiotics ([@ref10]). Indeed, although CF-301 showed a potent antibiofilm activity (MBEC~90~ values from 9 nM to 0.3 μM), it was improved when combining with lysostaphin ([@ref56]).

We also evaluated the *in vivo* activity of LysRODI and CHAPSH3b, by using a zebra fish model, which has been deemed suitable for assessing the efficacy of antimicrobial agents before proceeding to mammalian studies ([@ref12]). Initially, we observed that none of the proteins was toxic for zebrafish embryos at the dose tested. In a subsequent experiment, a single dose of either protein significantly reduced mortality of zebrafish by *S. aureus* in a systemic model of infection. Nevertheless, the treatment with CHAPSH3b seems to be dose dependent. Due to the positive results obtained in the zebrafish model, we decided to assess the efficacy of the protein that resulted in the best overall results (LysRODI) in a murine mastitis model. Even though the effectiveness of endolysins has been demonstrated *in vivo*, there is a lack of research regarding their safety and toxicity. Nevertheless, safety studies carried out with endolysins Cpl-1 and PaI supported the safety of these compounds, since there was no significant pro-inflammatory response, hypersensitivity or allergic reaction after injecting 0.3 mg per mouse (15 mg/kg) of each protein ([@ref29]). Moreover, toxicity in mammals is not a worrying issue since it has been proven that intravenous administration of endolysin SAL-200 (highly similar to LysRODI) showed no signs of toxicity in rodents after single- and repeated-dose experiments ([@ref32]). Moreover, SAL-200 was also administered (single intravenous) among healthy volunteers, with no adverse side-effects reported ([@ref31]).

The effectiveness of endolysins against staphylococcal infections in animal models has been widely demonstrated ([@ref24]). Specifically, for mastitis treatment, two promising papers support the use of phage lytic proteins as therapeutic agents. [@ref52] demonstrated that the infusion of a combination of proteins (ƛSA2-E-LysK-SH3b and lysostaphin, 12.5 μg each/gland) caused a 3.36-log decrease in viable bacteria and a reduction in inflammation indicators in a murine mastitis. More recently, preliminary results showed that endolysin Trx-SA1 (20 mg once per day) could effectively control mild clinical mastitis caused by *S. aureus* in cows ([@ref15]). Nonetheless, an endolysin-based treatment could be challenging, as bacterial cells could form biofilms on host tissues or live intracellularly. For this reason, it would be preferable to perform preventive rather than therapeutic treatments. However, few reports have been published about prophylaxis of infectious diseases caused by *S. aureus* using phage lytic proteins and none regarding *S. epidermidis*. Indeed, the emergence of *S. aureus* resistance to mupirocin has led clinicians to rethink its use for nasal decolonization in certain groups of patients ([@ref7]). In contrast, phage lytic proteins like ClyS have shown a greater potential than mupirocin for topical eradication of this bacterium and a lower potential for resistance development ([@ref42]). Here, we proved that intrammamary infusion of 24 μg (0.43 μM) of LysRODI can protect mice from *S. aureus* and *S. epidermidis* mastitis. It is also worth noting that no resistant bacteria were obtained after sub-lethal exposure to the proteins. Previous studies found similar results with other endolysins ([@ref42]; [@ref24]), with the exception of LysK, which led to a 42-fold MIC increase in *S. aureus* liquid cultures ([@ref4]). Nonetheless, in the case of bovine mastitis, the use of endolysins as prophylaxis (every animal is treated on a regular basis by intramammary infusion) or as treatment needs to be evaluated in detail, due to the expected high cost derived from production of these enzymes.

Overall, phage lytic proteins offer ideal features, including their easy manipulation for designing new proteins with improved activity and the lack of bacterial resistance development, to be used as therapeutic agents and as decolonizing products for veterinary applications.
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